We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Rexahn Pharmaceuticals Submits Serdaxin® Phase II Protocol to FDA for Parkinson’s Disease

News   Apr 07, 2010

 
Rexahn Pharmaceuticals Submits Serdaxin® Phase II Protocol to FDA for Parkinson’s Disease
 
 
 

RELATED ARTICLES

Postmortem Diagnosis Improved by Minimally Invasive Techniques

News

Minimally invasive autopsy with CT and MRI performs as well as conventional autopsy in detecting cause of death and has the advantage of yielding more diagnoses.

READ MORE

We are Bombarded by Thousands of Diverse Species and Chemicals

News

The human 'exposome,' i.e. particulates, chemicals and microbes that bombard us, has been measured in impressive detail.

READ MORE

Enzymes 'Partner Up' to Accelerate Cancer and Aging Diseases

News

Research on telomeres at Indiana University could help advance new strategies to stop runaway cellular growth.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE